Attached files
| file | filename |
|---|---|
| 10-K - Altimmune, Inc. | v178541_10k.htm |
| EX-21 - Altimmune, Inc. | v178541_ex21.htm |
| EX-31.2 - Altimmune, Inc. | v178541_ex31-2.htm |
| EX-31.1 - Altimmune, Inc. | v178541_ex31-1.htm |
| EX-32.2 - Altimmune, Inc. | v178541_ex32-2.htm |
| EX-32.1 - Altimmune, Inc. | v178541_ex32-1.htm |
| EX-10.30.1 - Altimmune, Inc. | v178541_ex10-30.htm |
| EX-10.30.2 - Altimmune, Inc. | v178541_ex10-31.htm |
Consent
of Independent Registered Public Accounting Firm
We
consent to the incorporation by reference in the following Registration
Statements:
(1)
Registration Statement (Form S-3 No. 333-146463),
(2)Registration
Statement (Form S-3 No. 333-155692),
(3)
Registration Statement (Form S-8 No. 333-156371) pertaining to the 2007
Long-Term Incentive Compensation Plan,
(4)
Registration Statement (Form S-3 No. 333-156997),
(5)
Registration Statement (Form S-3 No. 333-124712), and
(6)
Registration Statement (Form S-3 No. 333-161587),
of
PharmAthene, Inc. and in the related Prospectuses of our report dated March 26,
2010, with respect to the consolidated financial statements of PharmAthene,
Inc., included in this Annual Report (Form 10-K). for the year ended December
31, 2009.
|
/s/
Ernst & Young LLP
|
McLean,
Virginia
March 26,
2010